Site Editors

Shaji K. Kumar, MD

Prashant Kapoor, MD, FACP


Update on New CAR T-Cell Therapy for Resistant Myeloma From Multicenter Study

By: Julia Fiederlein Cipriano, MS
Posted: Tuesday, September 5, 2023

According to Carlos Fernández de Larrea, MD, PhD, of the Hospital Clínic de Barcelona, and colleagues, in patients with relapsed or refractory multiple myeloma, the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy ARI0002h may provide deep and sustained responses when administered in a fractioned manner with a booster dose after 3 months. The results of an interim analysis from the multicenter CARTBCMA-HCB-01 trial, which were published in The Lancet Oncology, highlighted the treatment’s low neurologic toxicity and potential for point-of-care manufacturing.

“CAR T-cell therapy is a promising option for patients with heavily treated multiple myeloma,” the investigators remarked. “Point-of-care manufacturing can increase the availability of these treatments worldwide.”

A total of 30 patients who received at least two prior lines of therapy (including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody) were administered a fractionated infusion of 3 x 106/kg CAR-positive cells in three aliquots. After at least 100 days, they received a nonfractionated booster dose of up to 3 x 106/kg CAR-positive cells. Follow-up data were provided for a median of 12.1 months.

The investigators reported an overall response rate of 100% during the first 100 days after infusion, including a complete response rate of 50%, a very good partial response rate of 30% , and a partial response rate of 20%. Cytokine-release syndrome was observed in the majority of patients (80%; all grade 1 or 2). No cases of neurotoxic events were reported. A total of 67% of patients experienced persistent cytopenias of grade 3 or 4. Infections were reported in approximately two-thirds of the study population (67%). Three patients died during therapy: one from disease progression, one from a head injury, and one from COVID-19.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.